377 related articles for article (PubMed ID: 31091136)
1. Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.
Perrot A; Lauwers-Cances V; Tournay E; Hulin C; Chretien ML; Royer B; Dib M; Decaux O; Jaccard A; Belhadj K; Brechignac S; Fontan J; Voillat L; Demarquette H; Collet P; Rodon P; Sohn C; Lifermann F; Orsini-Piocelle F; Richez V; Mohty M; Macro M; Minvielle S; Moreau P; Leleu X; Facon T; Attal M; Avet-Loiseau H; Corre J
J Clin Oncol; 2019 Jul; 37(19):1657-1665. PubMed ID: 31091136
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.
Jian Y; Chen X; Zhou H; Zhu W; Liu N; Geng C; Chen W
Medicine (Baltimore); 2016 May; 95(19):e3521. PubMed ID: 27175647
[TBL] [Abstract][Full Text] [Related]
3. Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.
Moreau P; Cavo M; Sonneveld P; Rosinol L; Attal M; Pezzi A; Goldschmidt H; Lahuerta JJ; Marit G; Palumbo A; van der Holt B; Bladé J; Petrucci MT; Neben K; san Miguel J; Patriarca F; Lokhorst H; Zamagni E; Hulin C; Gutierrez N; Facon T; Caillot D; Benboubker L; Harousseau JL; Leleu X; Avet-Loiseau H; Mary JY
J Clin Oncol; 2014 Jul; 32(20):2173-80. PubMed ID: 24888806
[TBL] [Abstract][Full Text] [Related]
4. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
5. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.
Avet-Loiseau H; Attal M; Campion L; Caillot D; Hulin C; Marit G; Stoppa AM; Voillat L; Wetterwald M; Pegourie B; Voog E; Tiab M; Banos A; Jaubert J; Bouscary D; Macro M; Kolb B; Traulle C; Mathiot C; Magrangeas F; Minvielle S; Facon T; Moreau P
J Clin Oncol; 2012 Jun; 30(16):1949-52. PubMed ID: 22547600
[TBL] [Abstract][Full Text] [Related]
6. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.
Hebraud B; Magrangeas F; Cleynen A; Lauwers-Cances V; Chretien ML; Hulin C; Leleu X; Yon E; Marit G; Karlin L; Roussel M; Stoppa AM; Belhadj K; Voillat L; Garderet L; Macro M; Caillot D; Mohty M; Facon T; Moreau P; Attal M; Munshi N; Corre J; Minvielle S; Avet-Loiseau H
Blood; 2015 Mar; 125(13):2095-100. PubMed ID: 25636340
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
[TBL] [Abstract][Full Text] [Related]
8. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
9. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
Avet-Loiseau H; Attal M; Moreau P; Charbonnel C; Garban F; Hulin C; Leyvraz S; Michallet M; Yakoub-Agha I; Garderet L; Marit G; Michaux L; Voillat L; Renaud M; Grosbois B; Guillerm G; Benboubker L; Monconduit M; Thieblemont C; Casassus P; Caillot D; Stoppa AM; Sotto JJ; Wetterwald M; Dumontet C; Fuzibet JG; Azais I; Dorvaux V; Zandecki M; Bataille R; Minvielle S; Harousseau JL; Facon T; Mathiot C
Blood; 2007 Apr; 109(8):3489-95. PubMed ID: 17209057
[TBL] [Abstract][Full Text] [Related]
10. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R;
Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516
[TBL] [Abstract][Full Text] [Related]
11. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.
Avet-Loiseau H; Hulin C; Campion L; Rodon P; Marit G; Attal M; Royer B; Dib M; Voillat L; Bouscary D; Caillot D; Wetterwald M; Pegourie B; Lepeu G; Corront B; Karlin L; Stoppa AM; Fuzibet JG; Delbrel X; Guilhot F; Kolb B; Decaux O; Lamy T; Garderet L; Allangba O; Lifermann F; Anglaret B; Moreau P; Harousseau JL; Facon T
J Clin Oncol; 2013 Aug; 31(22):2806-9. PubMed ID: 23796999
[TBL] [Abstract][Full Text] [Related]
12. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.
Grzasko N; Hajek R; Hus M; Chocholska S; Morawska M; Giannopoulos K; Czarnocki K; Druzd-Sitek A; Pienkowska-Grela B; Rygier J; Usnarska-Zubkiewicz L; Dytfeld D; Kubicki T; Jurczyszyn A; Korpysz M; Dmoszynska A
Leuk Lymphoma; 2017 Sep; 58(9):1-15. PubMed ID: 28092996
[TBL] [Abstract][Full Text] [Related]
13. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.
Leleu X; Karlin L; Macro M; Hulin C; Garderet L; Roussel M; Arnulf B; Pegourie B; Kolb B; Stoppa AM; Brechiniac S; Marit G; Thielemans B; Onraed B; Mathiot C; Banos A; Lacotte L; Tiab M; Dib M; Fuzibet JG; Petillon MO; Rodon P; Wetterwald M; Royer B; Legros L; Benboubker L; Decaux O; Escoffre-Barbe M; Caillot D; Fermand JP; Moreau P; Attal M; Avet-Loiseau H; Facon T;
Blood; 2015 Feb; 125(9):1411-7. PubMed ID: 25575538
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects.
Sergentanis TN; Kastritis E; Terpos E; Dimopoulos MA; Psaltopoulou T
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):335-40. PubMed ID: 27101987
[TBL] [Abstract][Full Text] [Related]
16. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
Avet-Loiseau H; Malard F; Campion L; Magrangeas F; Sebban C; Lioure B; Decaux O; Lamy T; Legros L; Fuzibet JG; Michallet M; Corront B; Lenain P; Hulin C; Mathiot C; Attal M; Facon T; Harousseau JL; Minvielle S; Moreau P;
Blood; 2011 Feb; 117(6):2009-11. PubMed ID: 20962323
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
Avet-Loiseau H; Leleu X; Roussel M; Moreau P; Guerin-Charbonnel C; Caillot D; Marit G; Benboubker L; Voillat L; Mathiot C; Kolb B; Macro M; Campion L; Wetterwald M; Stoppa AM; Hulin C; Facon T; Attal M; Minvielle S; Harousseau JL
J Clin Oncol; 2010 Oct; 28(30):4630-4. PubMed ID: 20644101
[TBL] [Abstract][Full Text] [Related]
18. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
Merz M; Hielscher T; Seckinger A; Hose D; Mai EK; Raab MS; Goldschmidt H; Jauch A; Hillengass J
Am J Hematol; 2016 Nov; 91(11):E473-E477. PubMed ID: 27508939
[TBL] [Abstract][Full Text] [Related]
19. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
[TBL] [Abstract][Full Text] [Related]
20. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Schavgoulidze A; Talbot A; Perrot A; Cazaubiel T; Leleu X; Manier S; Buisson L; Mahéo S; Do Souto Ferreira L; Pavageau L; Hulin C; Marolleau JP; Voillat L; Belhadj K; Divoux M; Slama B; Brechignac S; Macro M; Stoppa AM; Sanhes L; Orsini-Piocelle F; Fontan J; Chretien ML; Demarquette H; Mohty M; Avet-Loiseau H; Corre J
Blood; 2023 Mar; 141(11):1308-1315. PubMed ID: 36375118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
